

# 14β-O-Cinnamoylnaltrexone and Related Dihydrocodeinones are Mu Opioid Receptor Partial Agonists with Predominant Antagonist Activity

H. Moynihan,<sup>†</sup> A. R. Jales,<sup>†</sup> B. M. Greedy,<sup>‡</sup> D. Rennison,<sup>‡</sup> J. H. Broadbear,<sup>§</sup> L. Purington,<sup>§</sup> J. R. Traynor,<sup>§</sup> J. H. Woods,<sup>§</sup> J. W. Lewis,<sup>‡</sup> and S. M. Husbands<sup>\*,‡</sup>

Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K., School of Chemistry, University of Bristol, Bristol BS8 1TS, U.K., and Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109

Received September 29, 2008

14-*O*-Cinnamoyl esters of naltrexone (**6**) were synthesized and evaluated in isolated tissue assays *in vitro* and *in vivo* in mouse antinociceptive assays. Their predominant opioid receptor activity was mu receptor (MOR) antagonism, but the unsubstituted cinnamoyl derivative (**6a**) had partial MOR agonist activity *in vitro* and *in vivo*. When compared to the equivalent 14-cinnamoylaminomorphinones (**5**), the cinnamoyloxy morphinones (**6**) as MOR antagonists had a shorter duration of action and were less effective as pseudoirreversible antagonists. The antinociceptive activity of the cinnamoyloxycodeinones (**7**) was not significantly greater than that of the morphinones (**6**), but they exhibited no evidence of any pseudoirreversible MOR antagonism. In both respects, these profiles differed from those of the equivalent 14-cinnamoylaminocodeinones (**4**).

## Introduction


Naloxone (**1b**) and naltrexone (**1a**) are prototype opioid antagonists having some limited selectivity for mu opioid receptors (MORs). They have found clinical utility as a treatment for opiate<sup>1</sup> and alcohol dependence<sup>2</sup> and in reversing narcotic overdose.<sup>3</sup> 14-*O*-Alkyl ethers (**2**) of naltrexone retain predominant MOR antagonist activity,<sup>4,5</sup> but the 14-*O*-3-phenylpropyl ether (**2a**) has recently been shown to have high-efficacy and high-potency MOR agonist activity in antinociceptive assays.<sup>6</sup> We have conducted extensive studies of derivatives (**3**) of 14β-amino-7,8-dihydromorphinone with a major focus on the cinnamoylamino derivatives (**4** and **5**), of which the MOR-selective irreversible antagonists cloccinamox [C-CAM (**5b**)] and methcinnamox [M-CAM (**5c**)] are the most studied examples.<sup>7–10</sup> We here report preparation and evaluation of 14-*O*-cinnamoyl esters of naltrexone (**6**) and the equivalent codeinones (**7**) for comparison with the 14-amino derivatives (**4** and **5**) and with the 14-*O*-phenylpropyl ether of naltrexone (**2a**).

## Synthesis

Acylation of naltrexone 3-*O*-methyl ether (**8a**) to give **7a–c** was achieved using the appropriate anhydrides (Scheme 1), themselves prepared from their equivalent acid chlorides by the method of Armesto et al.<sup>11</sup> Ligands **6a–c** were similarly prepared from 3-*O*-(*tert*-butyldimethylsilyl)naltrexone (**8b**)<sup>12</sup> by acylation and then removal of the protecting group with potassium fluoride to yield the morphinones (Scheme 1).

## Results

The new ligands (**6** and **7**) in opioid receptor binding assays<sup>13,14</sup> displayed high affinity for MOR and significantly



lower affinity for delta opioid receptors (DORs) and kappa opioid receptors (KORs) (Table 1). The affinity of the morphinones (**6**) was generally higher than that of the codeinones (**7**), with DOR affinity showing greater disparity than MOR and KOR affinity. The unsubstituted cinnamoylmorphinone (**6a**) had the highest affinity for all three receptors, comparable to that of naltrexone, and for MOR, higher than C-CAM (**5b**).

The morphinones (**6**) were evaluated for opioid receptor functional activity in the mouse vas deferens (MVD) and guinea pig ileum (GPI) isolated tissue assays.<sup>13</sup> In MVD, the morphinones displayed little agonist activity but were very potent opioid receptor antagonists of the standard selective opioid receptor agonists DAMGO (MOR), DPDPE (DOR), and U69593 (KOR), having subnanomolar *K<sub>i</sub>* values for all three opioid receptors (Table 2). Although MOR antagonist potency was higher than DOR and KOR potency, there was no appreciable selectivity for MOR over DOR and KOR. In GPI, morphinones **6** partially inhibited the electrically stimulated contractions of the tissue. This opioid receptor partial agonist effect was not reversed by selective antagonists CTAP (MOR) or norBNI (KOR), indicating very slow receptor offset like that observed with the similarly lipophilic opioid ligands buprenorphine (**10**)<sup>15</sup> and C-CAM (**5b**).<sup>16</sup>

\* To whom correspondence should be addressed: Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, U.K. Telephone: 44-(0)1225 383103. Fax: 44-(0)1225 386114. E-mail: s.m.husbands@bath.ac.uk.

<sup>†</sup> University of Bristol.

<sup>‡</sup> University of Bath.

<sup>§</sup> University of Michigan.

**Table 1.** Binding Affinities of New Ligands for Opioid Receptors

	R'	K <sub>i</sub> (nM) <sup>d</sup>		
		MOR	DOR	KOR
<b>6a</b> <sup>a</sup>	H	0.40 ± 0.05	3.4 ± 0.8	3.6 ± 2
<b>6b</b> <sup>a</sup>	Cl	1.3 ± 0.45	15 ± 6	8.3 ± 0.2
<b>6c</b> <sup>a</sup>	CH <sub>3</sub>	3.3 ± 0.1	19 ± 0.6	8.1 ± 0.7
<b>7a</b> <sup>b</sup>	H	2.5 ± 0.7	180 ± 58	4.3 ± 0.7
<b>7b</b> <sup>b</sup>	Cl	3.5 ± 1.0	110 ± 20	52 ± 12
<b>7c</b> <sup>b</sup>	CH <sub>3</sub>	4.2 ± 1.5	270 ± 80	36 ± 8.0
naltrexone <sup>a</sup> ( <b>1</b> )		0.40 ± 0.05	6.5 ± 1	0.6 ± 0.1
naltrexone <sup>b</sup> ( <b>1</b> )		0.20 ± 0.0	11 ± 3	0.4 ± 0.1
MC-CAM <sup>b</sup> ( <b>4b</b> )		4.8 ± 0.6	4.8 ± 0.7	16 ± 2.5
C-CAM <sup>b</sup> ( <b>5b</b> )		3.0 ± 0.2	2.7 ± 0.2	1.4 ± 0.5
PPN ( <b>2a</b> ) <sup>b,c</sup>		0.34 ± 0.06	0.48 ± 0.05	0.41 ± 0.09

<sup>a</sup> Binding to guinea pig brain membranes (method in ref 13). <sup>b</sup> Binding to cloned human opioid receptors transfected into CHO cells (method in ref 14). <sup>c</sup> Figures from ref 6. <sup>d</sup> Values are the average from two experiments each carried out in duplicate. Tritiated ligands were [<sup>3</sup>H]DAMGO (MOR), [<sup>3</sup>H]Cl-DPDPE (DOR), and [<sup>3</sup>H]U69593 (KOR).

**Table 2.** Antagonist Activity of New Ligands in the Mouse Vas Deferens

	R'	K <sub>c</sub> <sup>a</sup> (nM)		
		MOR	DOR	KOR
<b>6a</b>	H	0.020 ± 0.007	0.25 ± 0.06	0.19 ± 0.06
<b>6b</b>	Cl	0.060 ± 0.03	0.060 ± 0.01	1.3 ± 0.2
<b>6c</b>	CH <sub>3</sub>	0.12 ± 0.02	0.66 ± 0.2	0.54 ± 0.07
naltrexone ( <b>1</b> )		0.44 ± 0.09	7.2 ± 0.3	8.0 ± 0.6

<sup>a</sup> K<sub>c</sub> vs the standard selective agonists DAMGO (MOR), DPDPE (DOR), and U69593 (KOR). Values are the average of at least four experiments.

**Table 3.** Inhibition of Agonist-Stimulated [<sup>35</sup>S]GTPγS Binding in Recombinant Human Opioid Receptors

	R'	MOR K <sub>c</sub> (nM) <sup>a</sup>	DOR K <sub>c</sub> (nM) <sup>b</sup>	KOR K <sub>c</sub> (nM) <sup>c</sup>
<b>7a</b>	H	agonist <sup>d</sup>	agonist <sup>d</sup>	agonist <sup>d</sup>
<b>7b</b>	Cl	8.2 ± 0.34	57 ± 2.2	96 ± 14
<b>7c</b>	CH <sub>3</sub>	6.4 ± 0.35	not tested	agonist <sup>d</sup>
MC-CAM ( <b>4b</b> )		0.97 ± 0.15	7.2 ± 0.57	9.8 ± 0.88
naltrexone ( <b>1</b> )		0.59 ± 0.04	5.4 ± 0.75	1.9 ± 0.16
C-CAM ( <b>5b</b> )		0.53 ± 0.12	0.19 ± 0.02	0.10 ± 0.006



<sup>a</sup> K<sub>c</sub> vs DAMGO. <sup>b</sup> K<sub>c</sub> vs DPDPE. <sup>c</sup> K<sub>c</sub> vs U69593. <sup>d</sup> The agonist activity of these compounds is reported in Table 4.

**Table 4.** Opioid Agonist Stimulation of [<sup>35</sup>S]GTPγS Binding in Recombinant Human Opioid Receptors

	R'	EC <sub>50</sub> (nM); % stimulation <sup>a</sup>		
		MOR	DOR	KOR
<b>7a</b>	H	34.4 ± 5.0; 35	430 ± 110; 64	26 ± 4.9; 76
<b>7c</b>	CH <sub>3</sub>	ANT	not determined	157 ± 3.4; 37
MC-CAM ( <b>4b</b> ) <sup>b</sup>		17.8 ± 11; 8	not determined	ANT
morphine		15.6 ± 0.5; 93	316 ± 4.9; 103	484 ± 213; 62

<sup>a</sup> Percent maximal stimulation with respect to the standard agonists DAMGO (MOR), U69593 (KOR), and DPDPE (DOR). ANT indicates antagonist activity (K<sub>c</sub> values reported in Table 3). Values are the means of five or six experiments. Data supplied by NIDA Addiction Treatment Discovery Program. <sup>b</sup> Data from ref 19.

The opioid receptor functional activity of the codeinones (**7**) was investigated by their effects on stimulating [<sup>35</sup>S]GTPγS binding in the recombinant human opioid receptor transfected into CHO cells (Tables 3 and 4).<sup>14</sup> The unsubstituted cinnamoyl ester (**7a**) exhibited partial agonist activity of modest potency for all three opioid receptors (Table 4), whereas the *p*-chloro analogue (**7b**) had insignificant agonist activity for any opioid receptor but was an antagonist of the standard agonists DAMGO (MOR), DPDPE (DOR), and U69593 (KOR) (Table 3) which were also used as the standards against which the agonist stimulation of **7a**

**Figure 1.** Dose–response curves for morphine alone (■) and after pretreatment with a 32 mg/kg dose of morphinones **6a**, **6b**, and **6c** in the mouse warm water tail withdrawal assay. Pretreatment times (ptt) were 24 h (**6a**, **6b**, and **6c**) and 30 min (**6b**).**Scheme 1<sup>a</sup>**


<sup>a</sup> (i) (RCO)<sub>2</sub>O, toluene, reflux; (ii) KF, MeOH, CH<sub>2</sub>Cl<sub>2</sub>.

was measured. **7c** like **7b** had antagonist activity at MOR (Table 3) but was a KOR partial agonist (Table 4).


The in vivo activity of the 14-*O*-acyl derivatives was investigated in mouse antinociceptive tests using assays with thermal [tail withdrawal from 50 °C warm water (TW)]<sup>8</sup> or chemical [acetic acid-induced writhing (AW)] stimulation.<sup>8</sup> None of the naltrexone derivatives (**6** and **7**) exhibited any significant opioid receptor agonist activity in TW, but all were effective antagonists of morphine in this assay. A high dose (32 mg/kg given 30 min before morphine) of each of the morphinones (**6**) flattened the morphine dose–response curve up to 320–1000 mg/kg of the agonist (illustrated for **6b** in Figure 1). Pretreatment (24 h) with antagonist **6b** resulted in a 10-fold parallel rightward shift of the morphine dose–response curve, but the shift produced by **6a** and **6c** was negligible (Figure 1). The codeinones (**7b** and **7c**) were antagonists of morphine in TW but at 32 mg/kg shifted the morphine dose–effect curve in the standard assay only 3–4-fold to the right with no evidence of flattening, and there was no antagonist effect with a 24 h pretreatment (data not shown).

The para-substituted cinnamoyloxymorphinone **6c** and the equivalent codeinone **7c** unimpressively inhibited the acetic acid-induced writhing effect, whereas **6a** was substantially more potent and effective (Figure 2). The only opioid antagonists without any in vivo agonist effects were the *p*-chlorocinnamoyloxy derivatives (**6b** and **7b**). These data confirm that the chemical nociceptor used in the AW assay presents a less intense challenge than the thermal stimulus in TW.

<sup>a</sup> Abbreviations: TW, tail withdrawal from warm water; AW, acetic acid-induced writhing.



**Figure 2.** Inhibition of acetic acid-induced writhing by **6a**, **6c**, and **7c** after subcutaneous administration.



**Figure 3.** Agonist selectivity of **6a** (10 mg/kg, subcutaneous) in the writhing assay: NorBNI (KOR), 32 mg/kg (24 h pretreatment); β-FNA (MOR), 32 mg/kg (24 h pretreatment); and naltrindole (DOR), 10 mg/kg (24 h pretreatment). *t* test *p* values.

Agonist selectivity for the individual opioid receptor in AW was determined for **6a** by the use of selective antagonists for MOR, DOR, and KOR. These were antagonists β-FNA (MOR), naltrindole (DOR), and norBNI (KOR). β-FNA and norBNI were administered 24 h before **6a** to ensure a competitive (and selective) antagonist effect. The agonist effect of **6a** in AW was partially antagonized by β-FNA and by naltrindole but not by norBNI (Figure 3), so that it appears that in AW the agonist effects of **6a** are primarily mediated by DOR and MOR. **6b** was evaluated as an antagonist versus the agonists morphine (MOR), BW373U86 (DOR), and bremazocine (KOR), proving to be effective against only morphine with a 24 h pretreatment (data not shown).

## Discussion

Our prime interest in the activity of the naltrexone esters (**6**) was in comparison to the activity of the equivalent amides C-CAM (**5b**) and M-CAM (**5c**). The latter are highly effective and selective MOR antagonists with insignificant agonist effects in vivo.<sup>7,8</sup> They are more effective than β-FNA in flattening the dose–response curve of MOR agonists,<sup>8</sup> but since they do not form covalent bonds in vitro by Michael addition of protein nucleophilic groups, they have been termed pseudoirreversible antagonists.<sup>16,17</sup> The very powerful binding to MOR in vivo seems very likely to involve the lipophilic cinnamoylamino

group functioning in a manner similar to that of the *tert*-butyl group in buprenorphine (**10**).<sup>18</sup> The present 14-*O*-acylmorphinones (**6**) fell short of C-CAM and M-CAM as pseudoirreversible antagonists; though in TW they all flattened the morphine dose–response curve 30 min after their administration, their MOR antagonist effect was much reduced at 24 h, whereas the amides C-CAM (**5b**) and M-CAM (**5c**) had very pronounced MOR antagonist effects at 24 h and beyond.<sup>8</sup> **6b**, with *p*-chloro substitution in the cinnamoyl aromatic ring, was the most effective pseudoirreversible antagonist among the esters; its MOR antagonist profile was comparable to that of β-FNA.<sup>8</sup> Since, together with the corresponding codeinone (**7b**), **6b** was the only ester to lack any demonstrable antinociceptive action, the profile of **6b** is not dissimilar to that of C-CAM (**5b**). The unsubstituted morphinone ester **6a** in vivo was also basically similar to the equivalent amide **5a**.<sup>9</sup> This means it showed little agonist activity in TW but substantial activity in AW. Again the most significant difference between **6a** and **5a** is the duration of morphine antagonist activity in TW. **5a** with a 24 h pretreatment produced a 0.5–1 log unit shift of the morphine dose–response curve,<sup>9</sup> whereas the shift with **6a** was barely significant.

The biggest difference between the 14-cinnamoyloxy morphinones and equivalent 14-cinnamoylamino morphinones was found in the *p*-methyl-substituted derivatives (**6c** and **5c**). Whereas in the cinnamoylamino series M-CAM (**5c**) had no agonist activity in TW or AW and was a substantially more effective pseudoirreversible MOR agonist than the *p*-chloro analogue C-CAM (**5b**),<sup>8</sup> the *p*-methylcinnamoyloxy derivative **6c** was a less effective MOR antagonist than the *p*-chloro congener **6b** and had measurable agonist activity in AW. However, the SAR established for the 14-cinnamoylamino series (**5**) that the 4'-substituted derivatives (**5b** and **5c**) in vivo had lower MOR efficacy than the unsubstituted parent (**5a**)<sup>9</sup> also applied to the present 14-cinnamoyloxy series (**6**).

The cinnamoyloxy codeinones (**7b** and **7c**) in the antinociceptive assays had no agonist activity in TW and exhibited parallel rightward shifts of the morphine dose–response curve in this assay, indicating a competitive MOR antagonist effect. In AW, **7c** but not **7b** had a weak opioid receptor agonist effect. These profiles are not dissimilar to those of the equivalent morphinones (**6b** and **6c**) in the antinociceptive assays, the main difference being the lack of any flattening of the morphine dose–response curve by the codeinones in the MOR antagonist assay in TW. The similarity of the in vivo agonist effects of the cinnamoyloxycodeinones and morphinones contrasts with the 14-cinnamoylamino series in which the codeinones (**4**) all had substantially higher MOR efficacy in vivo than the equivalent morphinones (**5**).<sup>9</sup> In the in vitro functional assays (Tables 2 and 3), the cinnamoyloxymorphinones (**6b** and **6c**) were very much more potent as MOR antagonists than the equivalent codeinones (**7b** and **7c**). This contrasts with the very small difference in potency between the cinnamoylamino morphinone (C-CAM) and equivalent codeinone (MC-CAM) (Table 3).<sup>10</sup>

It is of interest to compare the activity of 14-cinnamoylnaltrexone (**6a**) with that of the phenylpropyl ether (**2a**) which is structurally similar in having a three-carbon chain linking the side chain aromatic ring to the C<sub>14</sub> oxygen atom. The ether (**2a**) in vivo gave a full response in a battery of thermal antinociceptive assays with potency up to 400 times greater than that of morphine.<sup>7</sup> In comparison, the cinnamoyl ester has much more modest in vitro and in vivo MOR agonist activity. It must be assumed that the relative conformational restraint of the α,β-

unsaturated cinnamoyl ester prevents an optimum interaction with MOR in the preferred agonist conformation.

## Conclusions

The 14-*O*-cinnamoyl esters of naltrexone have predominant opioid receptor antagonist activity both in vitro and in vivo. In this regard, they are similar to the equivalent 14-*N*-cinnamoylamino derivatives, but the latter are more potent antagonists with longer duration. Additionally, the naltrexone esters (**6**) have in vivo and in vitro MOR efficacy similar to that of the corresponding codeinones (**7**), whereas the codeinone amides (**4**) have substantially higher MOR efficacy than the morphinones (**5**). These differences are less significant than the difference between 14-cinnamoylnaltrexone (**6a**) and 14-*O*-phenylpropylnaltrexone (**2a**). The greater side chain conformational freedom of the latter allows it to display very high potency in vivo MOR agonist activity.

## Experimental Section

Column chromatography was performed under gravity, over silica gel 60 (35–70 mm) purchased from Merck. Analytical TLC was performed using aluminum-backed plates coated with Kieselgel 60 F<sub>254</sub>, from Merck. The chromatograms were visualized using either UV light (UVGL-58, short wavelength), ninhydrin (acidic), or potassium permanganate (basic). Melting points were carried out using a Reichert-Jung Thermo Galen Kofler block or a Gallenkamp MFB-595 melting point apparatus and are uncorrected. High- and low-resolution electron impact (EI) mass spectra were recorded using EI ionization at 70 eV, on a VG AutoSpec instrument, equipped with a Fisons autosampler. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded using a JEOL 270 (operating at 270 MHz for <sup>1</sup>H and 67.8 MHz for <sup>13</sup>C) spectrometer. Chemical shifts ( $\delta$ ) are measured in parts per million. Spectra were referenced internally using TMS as the standard. Only diagnostic peaks have been quoted for proton NMR. Microanalysis was performed with a Perkin-Elmer 240C analyzer. Chemicals and solvents were purchased from Aldrich Chemical Co. Compounds were submitted for testing as their oxalate salts, formed by adding 1 equiv of oxalic acid to an ethanolic solution of the ligand.

**3-*O*-(*tert*-Butyldimethylsilyl)-14 $\beta$ -cinnamoyloxy-*N*-cyclopropylmethyl-7,8-dihydronormorphinone (**9a**).** A solution of **8b** (593 mg, 1.3 mmol) and cinnamoyl anhydride (830 mg, 3.0 mmol) in dry toluene (12 mL) was heated to reflux for 3 h. After cooling, the reaction mixture was washed with a sodium bicarbonate solution (2  $\times$  5 mL) and water (5 mL) and dried over magnesium sulfate, and the solvent was removed in vacuo. The residue was purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>:MeOH, 49:1) to give **9a** (269 mg, 44%): EIMS *m/z* 585 (M<sup>+</sup>); HRMS (EI) *m/z* 585.2925 (M<sup>+</sup>), C<sub>35</sub>H<sub>43</sub>NO<sub>5</sub>Si requires 585.2910; <sup>1</sup>H NMR  $\delta$  0.07 (2H, m), 0.19 (3H, s), 0.28 (3H, s), 0.44 (2H, m), 0.74 (1H, m), 1.00 (9H, s), 4.69 (1H, s), 6.57 (1H, d), 6.59 (1H, d), 6.66 (1H, d), 7.70 (1H, d); <sup>13</sup>C NMR  $\delta$  -4.64, -4.48, 3.75, 4.00, 9.49, 18.29, 23.24, 25.75, 26.99, 30.45, 35.75, 43.97, 51.08, 55.46, 59.31, 82.77, 89.95, 119.31, 119.37, 122.55, 126.39, 128.20, 128.71, 130.39, 134.39, 138.01, 144.01, 146.80, 165.85, 207.22.

**14 $\beta$ -Cinnamoyloxy-*N*-cyclopropylmethyl-7,8-dihydronormorphinone (**6a**).** A solution of **9a** (140 mg, 0.24 mmol) and potassium fluoride (35 mg, 0.60 mmol) in MeOH (11 mL) and CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was stirred for 1 h at ambient temperature. Solvent evaporation gave a residue that was purified by silica gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub>:MeOH, 49:1) to give **6a** as a white foam (57%): EIMS *m/z* 505 (M<sup>+</sup>); <sup>1</sup>H NMR  $\delta$  0.05 (2H, m), 0.43 (2H, m), 0.76 (1H, m), 4.83 (1H, s), 6.58 (1H, d), 6.62 (1H, d), 6.80 (1H, d), 7.38 (3H, m), 7.56 (2H, m), 7.72 (1H, d); <sup>13</sup>C NMR  $\delta$  3.71, 4.00, 9.46, 23.18, 27.11, 30.19, 35.78, 44.00, 51.43, 55.56, 59.31, 82.77, 90.26, 118.29, 119.28, 120.07, 125.18, 128.39, 128.93, 129.31, 130.39, 134.39, 138.90, 143.53, 144.74, 165.88, 209.22. Anal. (C<sub>29</sub>H<sub>29</sub>NO<sub>5</sub>·(CO<sub>2</sub>H)<sub>2</sub>·2H<sub>2</sub>O) C, H, N.

**3-*O*-(*tert*-Butyldimethylsilyl)-14 $\beta$ -(4-chlorocinnamoyloxy)-*N*-cyclopropylmethyl-7,8-dihydronormorphinone (**9b**).** **8b** (429 mg, 0.94 mmol) and 4-chlorocinnamoyl anhydride (616 mg, 1.77 mmol) were treated like **9a** to yield **9b** as a clear oil (228 mg, 21%): EIMS *m/z* 619 (M<sup>+</sup>); HRMS (EI) *m/z* 619.2537 (M<sup>+</sup>), C<sub>35</sub>H<sub>42</sub>NO<sub>5</sub>Si requires 619.2521; <sup>1</sup>H NMR  $\delta$  0.04 (2H, m), 0.19 (3H, s), 0.27 (3H, s), 0.44 (2H, m), 0.72 (1H, m), 1.02 (9H, s), 4.67 (1H, s), 6.55 (1H, d), 6.56 (1H, d), 6.66 (1H, d), 7.28 (2H, d), 7.52 (2H, d), 7.65 (1H, d); <sup>13</sup>C NMR  $\delta$  -4.70, -4.54, 3.68, 3.94, 9.46, 18.25, 23.21, 25.68, 26.92, 30.45, 35.68, 43.94, 51.02, 55.43, 59.27, 82.96, 89.53, 119.34, 119.85, 122.55, 126.32, 128.61, 129.18, 129.31, 132.86, 136.23, 137.98, 143.12, 146.72, 165.53, 207.06.

**14 $\beta$ -(4-Chlorocinnamoyloxy)-*N*-cyclopropylmethyl-7,8-dihydronormorphinone (**6b**).** **9b** was treated with KF as described for **6a** to yield **6b** as a white foam (77%): EIMS *m/z* 505 (M<sup>+</sup>); <sup>1</sup>H NMR  $\delta$  0.04 (2H, m), 0.45 (2H, m), 0.74 (1H, m), 4.80 (1H, s), 6.57 (1H, d), 6.62 (1H, d), 6.76 (1H, d), 7.36 (2H, d), 7.50 (2H, d), 7.64 (1H, d); <sup>13</sup>C NMR  $\delta$  3.68, 3.97, 9.43, 23.11, 27.08, 30.19, 35.75, 43.97, 51.40, 55.46, 59.27, 82.93, 90.19, 118.26, 119.82, 120.01, 125.15, 128.16, 129.18, 129.31, 132.86, 136.23, 138.83, 143.21, 143.50, 165.56, 209.09. Anal. (C<sub>29</sub>H<sub>28</sub>NO<sub>5</sub>·(CO<sub>2</sub>H)<sub>2</sub>·2.5H<sub>2</sub>O) C, H, N.

**3-*O*-(*tert*-Butyldimethylsilyl)-14 $\beta$ -(4-methylcinnamoyloxy)-*N*-cyclopropylmethyl-7,8-dihydronormorphinone (**9c**).** **8b** (584 mg, 1.28 mmol) and 4-methylcinnamoyl anhydride (690 mg, 2.25 mmol) were treated like **9a** to yield **9c** as a clear oil (424 mg, 55%): EIMS *m/z* 599 (M<sup>+</sup>); HRMS (EI) *m/z* 599.3088, C<sub>36</sub>H<sub>45</sub>NO<sub>5</sub>Si requires 599.3067; <sup>1</sup>H NMR  $\delta$  0.05 (2H, m), 0.21 (3H, s), 0.29 (3H, s), 0.44 (2H, m), 0.75 (1H, m), 0.99 (9H, s), 2.38 (3H, s), 4.67 (1H, s), 6.53 (1H, d), 6.56 (1H, d), 6.65 (1H, d), 7.19 (2H, d), 7.48 (2H, d), 7.68 (1H, d); <sup>13</sup>C NMR  $\delta$  -4.70, -4.51, 3.71, 4.48, 9.46, 18.25, 21.46, 23.24, 25.21, 30.70, 32.73, 35.68, 43.94, 51.05, 55.53, 59.30, 82.57, 89.56, 118.16, 119.31, 122.51, 126.36, 127.69, 128.61, 129.78, 137.98, 140.36, 143.34, 144.56, 146.77, 165.98, 207.09.

**14 $\beta$ -(4-Methylcinnamoyloxy)-*N*-cyclopropylmethyl-7,8-dihydronormorphinone (**6c**).** **9c** was treated with KF as described for **9a** to yield **6c** as an oil (99%): EIMS *m/z* 485 (M<sup>+</sup>); <sup>1</sup>H NMR  $\delta$  0.04 (2H, m), 0.44 (2H, m), 0.72 (1H, m), 4.77 (1H, s), 6.53 (1H, d), 6.60 (1H, d), 6.75 (1H, d), 7.15 (2H, d), 7.48 (2H, d), 7.70 (1H, d); <sup>13</sup>C NMR  $\delta$  3.62, 3.90, 9.49, 21.46, 24.70, 26.32, 30.99, 32.79, 43.97, 51.46, 55.59, 59.34, 82.61, 90.29, 118.23, 120.01, 125.24, 127.94, 128.23, 129.66, 131.66, 132.04, 138.90, 140.80, 143.53, 144.71, 166.61, 209.06. Anal. (C<sub>30</sub>H<sub>31</sub>NO<sub>5</sub>·(CO<sub>2</sub>H)<sub>2</sub>·2H<sub>2</sub>O) C, H, N.

***N*-Cyclopropylmethyl-14 $\beta$ -cinnamoyloxy-7,8-dihydrocodeinone (**7a**).** A solution of **8a** (500 mg, 1.41 mmol) in anhydrous toluene (80 mL) was treated with cinnamoyl anhydride (512 mg, 1.84 mmol) and the resulting mixture heated to reflux and stirred overnight. Upon cooling, the solution was washed with a Na<sub>2</sub>CO<sub>3</sub> solution (2  $\times$  20 mL) and water (20 mL), dried over MgSO<sub>4</sub>, and evaporated to dryness. Silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>:MeOH: NH<sub>3</sub>, 198:1:1) gave **7a** as a white solid (303 mg, 44%): ESMS *m/z* 486 (MH<sup>+</sup>); HRMS (ES) *m/z* 486.2259 (MH<sup>+</sup>), C<sub>30</sub>H<sub>32</sub>NO<sub>5</sub> requires 486.2275; <sup>1</sup>H NMR  $\delta$  -0.01 to 0.08 (2H, m), 0.39–0.48 (2H, m), 0.69–0.77 (1H, m), 1.57–1.61 (1H, m), 1.69 (1H, dt), 2.13–2.20 (1H, m), 2.25–2.38 (3H, m), 2.53 (1H, dd), 2.60–2.75 (3H, m), 2.92–2.97 (1H, m), 3.11 (1H, d), 3.89 (3H, s), 4.58 (1H, d), 4.75 (1H, s), 6.57 (1H, d), 6.64 (1H, d), 6.71 (1H, d), 7.37–7.43 (3H, m), 7.56–7.60 (2H, m), 7.70 (1H, d); <sup>13</sup>C NMR  $\delta$  3.68, 3.90, 9.45, 23.06, 27.19, 30.26, 35.78, 43.93, 51.27, 55.43, 56.73, 59.29, 82.69, 90.13, 114.79, 119.22, 119.51, 125.88, 128.14, 128.64, 128.90, 130.35, 134.33, 142.92, 144.62, 144.88, 165.74, 207.54; mp (oxalate) 124–126 °C. Anal. (C<sub>30</sub>H<sub>31</sub>NO<sub>5</sub>·(CO<sub>2</sub>H)<sub>2</sub>·0.5H<sub>2</sub>O) C, H, N.

***N*-Cyclopropylmethyl-14 $\beta$ -4'-chlorocinnamoyloxy-7,8-dihydrocodeinone (**7b**).** **8a** (310 mg, 0.87 mmol) in anhydrous toluene (50 mL) was added to 4-chlorocinnamoyl anhydride (400 mg, 1.16 mmol) as described for **7a** to give **7b** as a white solid (110 mg, 24%): EIMS *m/z* 519 (M<sup>+</sup>); HRMS (EI) *m/z* 519.1822 (M<sup>+</sup>), C<sub>30</sub>H<sub>30</sub>NO<sub>5</sub>Cl requires 519.1813; <sup>1</sup>H NMR  $\delta$  0.01–0.12 (2H, m), 0.37–0.52 (2H, m), 0.67–0.82 (1H, m), 2.54 (1H, dd), 3.13 (1H,

d), 3.90 (3H, s), 4.58 (1H, d), 4.75 (1H, s), 6.56 (1H, d), 6.66 (1H, d), 6.73 (1H, d), 7.38 (2H, m), 7.52 (2H, m), 7.66 (1H, d); <sup>13</sup>C NMR δ 3.62, 3.88, 9.40, 23.04, 27.11, 30.23, 35.67, 43.89, 51.17, 55.39, 56.72, 59.22, 82.83, 90.02, 114.88, 119.49, 119.76, 125.78, 128.55, 129.12, 129.25, 132.79, 136.17, 142.88, 143.10, 144.84, 165.42, 207.33; mp (oxalate) 122–124 °C. Anal. (C<sub>30</sub>H<sub>30</sub>NO<sub>5</sub>Cl·(CO<sub>2</sub>H)<sub>2</sub>·0.5H<sub>2</sub>O) C, H, N.

**N-Cyclopropylmethyl-14β-4'-methylcinnamoyloxy-7,8-dihydrocodeinone (7c).** Using the same procedure described for **7b** but with 4-methylcinnamoyl anhydride gave **7c** (30%): EIMS *m/z* 499 (M<sup>+</sup>); HRMS (EI) *m/z* 499.2361 (M<sup>+</sup>), C<sub>31</sub>H<sub>33</sub>NO<sub>5</sub> requires 499.2359; <sup>1</sup>H NMR δ 0.06–0.13 (2H, m), 0.39–0.53 (2H, m), 0.69–0.82 (2H, m), 2.40 (3H, s), 2.55 (1H, dd), 3.13 (1H, d), 3.92 (3H, s), 4.60 (1H, d), 4.77 (1H, s), 6.55 (1H, d), 6.66 (1H, d), 6.74 (1H, d), 7.23 (2H, m), 7.49 (2H, m), 7.70 (1H, d); <sup>13</sup>C NMR δ 3.65, 3.85, 9.42, 21.43, 23.05, 27.16, 30.23, 35.73, 43.90, 51.22, 55.46, 56.73, 59.26, 82.50, 90.09, 114.86, 118.07, 119.47, 125.89, 128.09, 128.66, 129.58, 131.57, 140.74, 142.87, 144.57, 144.87, 165.89, 207.49; mp (oxalate) 126–128 °C. Anal. (C<sub>31</sub>H<sub>33</sub>NO<sub>5</sub>·(CO<sub>2</sub>H)<sub>2</sub>·0.5H<sub>2</sub>O) C, H, N.

**Acknowledgment.** This work was funded through NIDA Grants DA00254 and DA07315 and the in vitro characterization of compounds carried out through the NIDA Abuse Treatment Discovery Program (ATDP).

**Supporting Information Available:** Full experimental details and spectroscopic data (IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR, mass spectra, and microanalysis data), including biological assay methods. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References

- (1) Kreek, M. J. In *Handbook of Experimental Pharmacology*; Schuster, C. R., Kuhar, M. J., Eds.; Springer: Berlin, 1996; Vol. 118, p 563.
- (2) Pettinati, H. M.; O'Brien, C. P.; Rabinowitz, A. R.; Wortman, S. P.; Oslin, D. W.; Kampman, K. M.; Dackis, C. A. The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. *J. Clin. Psychopharmacol.* **2006**, *26*, 610–625.
- (3) Sporer, K. A. Acute heroin overdose. *Ann. Intern. Med.* **1999**, *130*, 84–90.
- (4) Kobylecki, R. J.; Carling, R. W.; Lord, J. A. H.; Smith, C. F. C.; Lane, A. C. Common anionic receptor site hypothesis: Its relevance to the antagonist action of naloxone. *J. Med. Chem.* **1982**, *25*, 116–120.
- (5) Schullner, F.; Meditz, R.; Krassnig, R.; Morandell, G.; Kalinin, V. N.; Sandler, E.; Spetea, M.; White, A.; Schmidhammer, H.; Berzetei-Gurske, I. Synthesis and biological evaluation of 14-alkoxymorphinans. 19. Effect of 14-O-benylation on the opioid receptor affinity and antagonist potency of naltrexone. *Helv. Chim. Acta* **2003**, *86*, 2335–2341.
- (6) Greiner, E.; Spetea, M.; Krassnig, R.; Schuller, F.; Aceto, M. D.; Harris, L. S.; Traynor, J. R.; Woods, J. H.; Coop, A.; Schmidhammer, H. Synthesis and biological evaluation of 14-alkoxymorphinans. 18.

N-Substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: Extending the scope of common structure-activity relationships. *J. Med. Chem.* **2003**, *46*, 1758–1763.

- (7) Aceto, M. D.; Bowmen, E. R.; May, E. L.; Woods, J. H.; Smith, C. B.; Medzihradsky, F.; Jacobson, A. E. Very long-acting narcotic antagonists: The 14β-*p*-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives. *Arzneim. Forsch.* **1989**, *39*, 570–575.
- (8) Broadbear, J. H.; Sumpter, T. L.; Burke, T. F.; Husbands, S. M.; Lewis, J. W.; Woods, J. H.; Traynor, J. R. Methcinnamox is a potent, long-lasting and selective antagonist of morphine-mediated antinociception in the mouse: Comparison with clocinnamox, β-FNA and β-chlornaltraxamine. *J. Pharmacol. Exp. Ther.* **2000**, *294*, 933–940.
- (9) Nieland, N. P. R.; Moynihan, H.; Carrington, S.; Broadbear, J.; Woods, J. H.; Traynor, J. R.; Husbands, S. M.; Lewis, J. W. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: Effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones. *J. Med. Chem.* **2006**, *49*, 5333–5338.
- (10) Rennison, D.; Moynihan, H.; Traynor, J. R.; Lewis, J. W.; Husbands, S. M. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: Effects of changes to the C14-amino to aryl ring linker chain. *J. Med. Chem.* **2006**, *49*, 6104–6110.
- (11) Armesto, N.; Ferrero, M.; Fernández, S.; Gotor, V. Novel enzymatic synthesis of 4-*o*-cinnamoyl quinic and shikimic acid derivatives. *J. Org. Chem.* **2003**, *68*, 5784–5787.
- (12) Nagase, H.; Abe, A.; Portoghese, P. S. The facility of formation of a Δ<sup>6</sup> bond in dihydromorphinone and related opiates. *J. Org. Chem.* **1989**, *54*, 4120–4125.
- (13) Toll, L.; Berzetei-Gurske, I. P.; Polgar, W. E.; Brandt, S. R.; Adapa, I. D.; Rodriguez, L.; Schwartz, R. W.; Haggart, D.; O'Brian, A.; White, A.; Kennedy, J. M.; Craymer, K.; Farrington, L.; Auh, J. S. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. *NIDA Res. Monogr.* **1998**, *178*, 440–466.
- (14) Zaveri, N.; Polgar, W. E.; Olsen, C. M.; Kelson, A. B.; Grundt, P.; Lewis, J. W.; Toll, L. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. *Eur. J. Pharmacol.* **2001**, *428*, 29–36.
- (15) Hambrook, J. M.; Rance, M. J. The interaction of buprenorphine with the opiate receptor. In *Opiates and Endogenous Opioid Peptides*; Kosterlitz, H. W., Ed.; Elsevier: Amsterdam, 1976; pp 295–301.
- (16) Zernig, G.; Butelman, E. R.; Lewis, J. W.; Walker, E. A.; Woods, J. H. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. *J. Pharmacol. Exp. Ther.* **1994**, *269*, 57–65.
- (17) Sebastian, A.; Bidlack, J. M.; Jiang, Q.; Deecher, D.; Teitler, M.; Glick, S. D.; Archer, S. 14β-[(*p*-Nitrocinnamoyl)amino]morphinones, 14β-[(*p*-nitrocinnamoyl)amino]-7,8-dihydromorphinones and their codeinone analogues: Synthesis and receptor activity. *J. Med. Chem.* **1993**, *36*, 3154–3160.
- (18) Husbands, S. M.; Lewis, J. W. Opioid ligands having delayed long-term antagonist activity: Potential pharmacotherapies for opioid abuse. *Mini-Rev. Med. Chem.* **2003**, *3*, 137–144.
- (19) Spagnolo, B.; Calo, G.; Polgar, W. E.; Jiang, F.; Olsen, C. M.; Berzetei-Gurske, I.; Khroyan, T. V.; Husbands, S. M.; Lewis, J. W.; Toll, L.; Zaveri, N. T. Activities of mixed NOP and μ-opioid receptor ligands. *Br. J. Pharmacol.* **2008**, *153*, 609–619.

JM8012272